Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I-II Study of Triciribine Phosphate Monohydrate (PTX-200) Plus Cytarabine in Refractory or Relapsed Acute Leukemia

NCT02930109 is registered in ClinicalTrials.gov with Prescient Therapeutics, Ltd. as lead sponsor.

NCT NCT02930109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02930109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I-II Study of Triciribine Phosphate Monohydrate (PTX-200) Plus Cytarabine in Refractory or Relapsed Acute Leukemia
Lead sponsor
Prescient Therapeutics, Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
December 9, 2016
Completion date
March 4, 2024
Enrollment
33 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute leukemia